StocksMedium•12 October 2026•
1 min read
Nurix Therapeutics Q3 Earnings Beat Estimates on Strong Revenue Growth
Key Facts
1Nurix Therapeutics reported GAAP EPS of $4.73, beating estimates by $1.64.
2The company's revenue reached $673.1M, surpassing estimates by $193.58M.
Nurix Therapeutics reported GAAP EPS of $4.73 for the third quarter, beating analyst estimates by $1.64 according to Seeking Alpha. The company's revenue reached $673.1 million during the period, surpassing expectations by $193.58 million.
NRIX closed at $22.35 on October 9, 2026, with the stock trading between a low of $21.23 and a high of $23.23 during that session. The company reported holding $1.1 billion in cash, cash equivalents, and marketable securities as of August 31, 2026, up from $592.9 million on November 30, 2025.